View Cart  
Fdanewsdrugdailybulletin

Feb. 22, 2005

Vol. 2 No. 37

View Archived Issues

Sign Up Now

Rising Medicare Cost Estimate Leads to Calls for Direct Price Negotiations

While drugmakers stand to gain financially under new cost estimates for the Medicare Rx drug benefit, the plan's significantly higher price tag also gives new ammunition to lawmakers who want the HHS to negotiate drug prices.

Read More

Adderall Sales Suspended in Canada

Health Canada has suspended the market authorization of Shire Pharmaceuticals' Adderall XR, saying a recent review of Shire safety data revealed an association between the attention-deficit/hyperactivity disorder drug and heart-related deaths and strokes in both children and adults.

Read More

Judge Sets Trial Date for Pharmacy Suit Over FDA's Drug-Compounding Policy

The FDA's current policy on drug compounding will be tested in court later this year, as a federal judge has given the green light to a lawsuit filed against the agency by a coalition of 10 pharmacies.

Read More

FDA Draft Guidance Addresses Trial Design for Clinical Lactation Studies

Drugmakers seeking approval of a product intended for use in women of reproductive age should conduct lactation studies on the drug, even in cases when the product would rarely be used in lactating women, according to a new FDA draft guidance.

Read More

Spectrum Pharmaceuticals Initiates Imitrex Patent Challenge

Spectrum Pharmaceuticals announced that it has initiated a challenge of the patent listed by GlaxoSmithKline in connection with GlaxoSmithKline's Imitrex injection 6mg/0.5mL

Read More

Sumitomo to Transfer Antitumor Antibiotic Sales to Nippon Kayaku

Sumitomo Pharmaceuticals has announced that it has signed a memorandum to transfer sales of its proprietary antitumor drug Calsed to Nippon Kayaku.

Read More

$86 Million Biotech Initial Public Offering

Five St. Louisans are making a bet on biotech. A big one. Dr. Frank O'Donnell plans to take his $26 million Accentia Biopharmaceuticals public.

Read More

Softwall Equipment Agrees to Acquire Inncardio

Softwall Equipment has announced that it has agreed to acquire Inncardio, a Delaware corporation engaged in the business of acquiring, developing and commercializing pharmaceutical products targeted at various Cardiovascular diseases.

Read More

Novartis Buys Generic Drugmakers Eon, Hexal

Novartis announced that it will buy generic drugmakers Eon Labs of the United States and Hexal of Germany for $8.3 billion, creating the world's largest generic drug company.

Read More

Quintiles, UNC-Chapel Hill Enter Clinical Research Alliance

Quintiles, the North American clinical development subsidiary of Quintiles Transnational, and the University of North Carolina at Chapel Hill have announced the creation of a new alliance for clinical research.

Read More

Ranbaxy to Set Up JV in Mexico

Ranbaxy Laboratories will set up a majority-owned joint venture in Mexico to tap the growing demand for generic drugs there. The joint venture with a Mexican firm will cater to the marketing and distribution demands of the local market.

Read More

Newron Pharmaceuticals Raises 30 Million Euros

Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced the raising of EUR 30 million (fully committed), out of which EUR 23 million closed.

Read More